R v Cantwell

The case of R v Cantwell involved a defendant accused of supplying a prohibited drug, which was not listed in Schedule 1 of the Drug Misuse and Trafficking Act. The court was tasked with determining whether the substance in question constituted a prohibited drug under the Act. The dispute hinged on whether the substance was an analogue of a drug listed in the Act, as well as the implications of the addition and replacement of atoms within the drug's molecular structure. The defendant argued that the drug in question, which had a halogen group added and a hydrogen atom removed, did not fall within the definition of a prohibited drug under the Act.

The primary legal issue before the court was whether the drug supplied by the defendant constituted a prohibited drug under the Act, specifically whether it was an analogue of a drug listed in Schedule 1. The court had to consider the definition of "analogue" and the impact of modifications to the molecular structure of the drug. The court examined whether the addition of a halogen group and the removal of a hydrogen atom constituted a significant alteration of the drug's structure, potentially removing it from the scope of the Act.

In delivering the judgment, the court held that the drug supplied by the defendant did not constitute a prohibited drug under the Act. The court found that the addition of a halogen group and the removal of a hydrogen atom resulted in a significant alteration of the drug's molecular structure, such that it was no longer an analogue of any drug listed in Schedule 1. The court emphasised that the Act's definition of "analogue" required a closer resemblance to the listed drugs than was present in this case. Consequently, the court found that the drug in question was not a prohibited drug under the Act.

The final orders of the court were that the drug supplied by the defendant was not a prohibited drug under the Drug Misuse and Trafficking Act. The court's decision provided clarity on the scope of the Act's analogue provisions and the impact of significant molecular alterations on the classification of drugs. This case serves as an important precedent for future cases involving the supply of drugs that have undergone significant molecular modifications.